Aethlon Medical, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, covering the second fiscal quarter of fiscal year 2027.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $6,486,639 as of September 30, 2026, up from $5,026,458 at March 31, 2026, according to the filing.
  • Total assets: The company reported total assets of $7,331,224 at September 30, 2026, compared to $6,333,107 at March 31, 2026.
  • Accumulated deficit: The accumulated deficit reached $179,271,705 as of September 30, 2026, versus $175,106,286 at March 31, 2026.
  • Shares outstanding: As of November 12, 2026, the company had 1,607,367 shares of common stock outstanding, $0.001 par value, up from 314,100 shares at March 31, 2026.
  • Total stockholders' equity: Stockholders' equity was $6,052,835 at September 30, 2026, compared to $4,886,272 at March 31, 2026.
  • Proposed merger: The filing references a proposed merger with North Immunology, Inc., including statements regarding anticipated timing, completion, and effects of the transaction, which the company characterizes as forward-looking and subject to risks.

Aethlon Medical's Balance Sheet and Strategic Developments at September 30, 2026

Aethlon Medical, Inc. (NASDAQ:AEMD), a Nevada-incorporated smaller reporting company headquartered in San Diego, California, filed its quarterly report covering the period ended September 30, 2026. According to the filing, the company held $6,486,639 in cash and cash equivalents at the close of the quarter, an increase from the $5,026,458 reported at the fiscal year-end date of March 31, 2026. Total current assets were $6,861,024, against total current liabilities of $1,278,389, with accounts payable of $743,525 representing the largest component of current obligations.

The filing disclosed that shares issued and outstanding rose sharply to 1,607,367 at September 30, 2026 from 314,100 at March 31, 2026, with additional paid-in capital increasing to $185,366,897 from $180,024,947 over the same period. The company's accumulated deficit grew by approximately $4.2 million during the six-month period, reaching $179,271,705. Total stockholders' equity improved to $6,052,835 from $4,886,272. The authorized share count remained at 20,000,000 for both balance sheet dates.

The filing also references the proposed merger with North Immunology, Inc., the potential monetization of the company's legacy Hemopurifier business, an ongoing oncology clinical trial in Australia, and plans to reduce operating expenses. The company characterizes all statements about these matters as forward-looking and notes they "are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict." The filing additionally discloses the company's efforts to maintain its Nasdaq listing and obtain additional financing as ongoing considerations.

What Was Disclosed

Aethlon Medical filed an unaudited quarterly report for the period ended September 30, 2026, disclosing balance sheet data, a significant increase in shares outstanding, a growing accumulated deficit, and details about its proposed merger with North Immunology, Inc.